Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02004392 · ClinicalTrials.gov registry record · Phase 3
Study of the Safety and Clinical Effects of 2 Doses of EVP-6124 in Subjects With Alzheimer's Disease Who Complete Study EVP-6124-024 or EVP-6124-025
A Phase 3 study, sponsored by FORUM Pharmaceuticals.
- Terminated
- Registry status
- Phase 3
- Development phase
- 348
- Enrollment target
NCT02004392: Clinical Trial Phase 3 study, sponsored by FORUM Pharmaceuticals.
NCT02004392 is a Phase 3 study that was terminated before completion, run by FORUM Pharmaceuticals. The registered enrollment target is 348 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (55% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02004392, a Phase 3 study, was terminated before completion, sponsored by FORUM Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 348 participants
- Enrollment target
Study Summary
This is a 26-week, randomized extension of the Phase 3 double-blind placebo-controlled studies, EVP-6124-024 and EVP-6124-025. In this extension study, subjects who complete study EVP-6124-024 or EVP-6124-025 and fulfill all entry criteria will be randomized to receive EVP-6124 for an additional 26 weeks.
Primary Outcome
Criteria for evaluation include: adverse events, clinical laboratory tests, vital signs, body weight, 12-lead ECG, physical examination, concomitant medications, C-SSRS, and GDS.
Interventions
- DRUG EVP-6124
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 348 participants |
| Start Date | 2014-06 |
| Est. Completion | 2017-08 |
| Phase | Phase 3 |
Why NCT02004392 stopped before completion
NCT02004392 is an interventional study that assigns participants to a tested intervention. The registered 348 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (55% lower).
The record links to 0 conditions, and to 1 intervention - of which EVP-6124 is the first listed.
NCT02004392 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02004392 about?
NCT02004392 is a clinical study titled "Study of the Safety and Clinical Effects of 2 Doses of EVP-6124 in Subjects With Alzheimer's Disease Who Complete Study EVP-6124-024 or EVP-6124-025". This is a 26-week, randomized extension of the Phase 3 double-blind placebo-controlled studies, EVP-6124-024 and EVP-6124-025. In this extension study, subjects who complete study EVP-6124-024 or EVP-6124-025 and fulfill all entry criteria will be randomized to receive EVP-6124 for an additional 26 ...
What is the current status of trial NCT02004392?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 348 participants. The study started on 2014-06. Estimated completion is 2017-08.
What interventions are being tested in trial NCT02004392?
The interventions under investigation include: EVP-6124 (DRUG).
Who is sponsoring clinical trial NCT02004392?
This trial is sponsored by FORUM Pharmaceuticals, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02004392's enrollment target sits among peer trials
348 1045th of 2000 higher than 953 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04041479 · 348 participants · Phase 3
Biomarker-guided rTMS for Treatment Resistant Depression
- NCT04530565 · 348 participants · Phase 3
Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults
- NCT05428735 · 348 participants · NA
The DRAGON 2 Trial
- NCT05787379 · 348 participants · NA
Care for Veterans Post-COVID-19
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia